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WORK PURPOSES
• To validate an analytical procedure based on WDXRF spectrometry for
the determination of 16 elemental impurities (As, Cd, Cr, Cu, Hg, Ir, Mn,
Mo, Ni, Os, Pb, Pd, Pt, Rh, Ru and V) in powdered pharmaceuticals
according to international regulatory guidelines;
• To monitor the concentration of these impurities in conventional
medicines and dietary supplements.
MATERIALS & METHODS
Equipment: 4 kW WDXRF spectrometer (S4 Pioneer, Bruker AXS).
Calibration and validation: According to ICH Guidelines. 8
Reagents: All reagents were of high analytical grade (≥99% Reagent or Ph
Eur).
Concentration ranges of calibration standards (ppm): 0-10 (Pb and Cd),
0-15 (Ir, Os, Pd, Pt, Rh and Ru), 0-25 (As and Hg), 0-30 (Cr, Mo, Ni and V)
and 0-300 (Cu, Mn).
STATE OF THE ART
Current requirements introduced by European Medicines Agency (EMA)
and United States Pharmacopeia (USP) for measurement of elemental
impurities in drug products present a challenge to the capacity of
existing analytical procedures for the monitor of these impurities in the
ppm range (Table 1).
According to USP, any alternative technique is considered acceptable and
equivalent to those procedures, provided that has been validated and
meets the acceptance criteria. 4
RESULTS & DISCUSSION
Linearity of the calibration function was excluded for As, Cd, Hg, Pd and
V. The USP stringent limits for As, Cd, Hg and Pb make difficult their
determination with the current analytical capacity of the WDXRF system
used. For Ru and Rh (with high LQ), the minimum number of required
replicated measurements was not met, which represents a limitation in
view of acceptance criteria.
.
Results obtained for drug
products and dietary
supplements may be
depicted in Figure 2.
CONCLUSIONS
• WDXRF technique may be an alternative to the compendial
recommended analytical procedures, with the advantage of an easier
and faster sample preparation, with no dissolutions or extractions,
allowing a truly direct sample measurement;
• The novelty of this work is the application of WDXRF to final
medicines consumed by the population and not only to active
pharmaceutical ingredients and/or excipients as reported so far.
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Table 1. Current EMA and USP limits for metals
impurities in pharmaceuticals (oral route) 1,2
Table 2. Linear calibration model estimated from 21 cellulose
standards
a SEE: Standard Error of the Estimate
Element 
Energy 
(keV) 
Intercept/KCPs Slope/KCps per % r SEEa 
Cr 5.4 0.455 ± 0.020 406.334 ± 11.338 0.993 0.051 
Cu 8.0 3.154 ± 0.216 2256.091 ± 11.789 0.999 0.522 
Ir 9.2 -0.120 ± 0.026 1124.715 ± 28.960 0.994 0.066 
Mn 5.9 0.030 ± 0.115 701.918 ± 6.742 0.999 0.289 
Mo 17.5 -7.547 ± 0.152 4834.405 ± 84.541 0.997 0.387 
Ni 7.5 0.435 ± 0.145 1782.352 ± 84.757 0.980 0.363 
Os 8.9 0.507 ± 0.018 1051.716 ± 19.770 0.997 0.045 
Pb 12.6 0.022 ± 0.021 1228.300 ± 38.003 0.991 0.060 
Pt 9.4 0.024 ± 0.019 1114.948 ± 20.750 0.997 0.048 
Ru 19.3 0.483 ± 0.007 101.636 ± 8.080 0.948 0.018 
Rh 20.2 0.029 ± 0.005 63.298 ± 5.805 0.928 0.013 
 
Element LD (ppm) 
Accuracy 
(% recovery) a,b 
Repeatability 
(%RSD) b,c 
Cr 1.62 88.0 [10]; 83.4 [15]; 84.2 [25] 1.0 [10]; 0.8 [25]; 1.1 [30] 
Cu 3.16 133.5 [50]; 78.9 [100]; 77.9 [250] 1.4 [100]; 1.2 [250]; 1.8 [300] 
Ir 0.76 93.9 [5]; 106.9 [10]; 88.1 [15] 9.1 [5]; 2.9 [10]; 2.1 [15] 
Mn 5.41 79.1 [50]; 95.0 [100]; 74.7 [250] 1.6 [100]; 0.7 [200]; 0.9 [300] 
Mo 1.04 107.7 [10]; 86.9 [25]; 86.4 [30] 1.3 [10]; 0.5 [15]; 1 [25] 
Ni 2.68 82.1 [10]; 71.3 [15]; 79.6 [25] 4.5 [10]; 0.4 [25]; 1.3 [30] 
Os 0.56 85.5 [5]; 68.7 [10]; 70.3 [15] 3.1 [5]; 3.6 [10]; 1.5 [15] 
Pt 0.55 66.5 [5]; 79.8 [10]; 70.3 [15] 2.9 [5]; 4.3 [10]; 2.1 [15] 
Ru 2.30 103.4 [10] 13.7 [10]; 16.1 [12]; 9.9 [15] 
Rh 2.60 114.9 [10] 7.8 [10]; 2.4 [12]; 6.2 [15] 
 
Table 3. Limits of detection, accuracy and precision under repeatability conditions of the
proposed WDXRF method
a Percent recovery of added amounts of analyte in drug samples, at 3 concentration levels, except for Ru and Rh; b Values
in brackets expressed in ppm; c Relative standard deviation (%RSD) of 3 replicate measurements.
At least 6 concentration levels
were considered for each
element.
SAMPLES: 27 drug products (6
branded, 21 generic) and
25 dietary supplements were
monitored (Figure 1).
In accordance with
international bodies, the
following validation
characteristics were
considered: specificity,
linearity and range, limit
of detection, limit of
quantification, accuracy
and precision (tables 2
and 3) . 8
Figure 1. Sample preparation
Figure 2. Number of samples with impurities above USP limits
13
20
2
1
Dietary supplements
Drug products
Mn Cr Ru
Disclosure of Interest: None Declared
Acknowledgements
To Egas Moniz CRL and Instituto de Ciências
Biomédicas Abel Salazar for the financial support
provided for this study.
ICH-Q3D document does not
impose any sample preparation
method or instrumental
technique, but USP<233> and
EP2.4.20 chapters list suitable
techniques for metal impurities
testing (ICP-AES, ICP-OES, AAS
and XRFS). 3-5 However, such
techniques have elevated costs
and require numerous reagents,
the destruction of the matrix by
acids mixtures, with risk of cross-
contamination or element losses
due to incomplete solubilization
or volatilization. 6,7
